COVID-19 Lesson: India Earmarks $1.3bn To Reduce Dependence On China
Lopinavir, Ritonavir On List Of 53 Incentivized APIs
Executive Summary
In a bid to ensure long-term medicines security, the Indian government has earmarked $1.32bn to promote domestic production of 53 APIs, including lopinavir and ritonavir currently being evaluated to treat COVID-19 cases, as well as antibiotics, for which India is highly dependent on China.
You may also be interested in...
APAC Regulatory Roundup: Infectious Disease A Common Theme As COVID Lingers
A roundup of key regulatory and policy developments in the Asia-Pacific in the first half of the year reveals broad developments across the region's diverse markets, although there seemed to be a common thread - a renewed focus on infectious diseases amid the lingering impact of the pandemic and the emergence of new threats.
World’s Largest Free Trade Bloc Hailed In China Amid Supply Chain Challenges
Covering nearly a third of the world’s population and roughly 30% of global GDP, the newly signed Regional Comprehensive Economic Partnership is set to accelerate trade within the Asia Pacific region. But India’s last-minute withdrawal means China may dominate the agenda going forward.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.